[go: up one dir, main page]

WO2008036967A3 - Novel heterocyclic compounds as lasy activators - Google Patents

Novel heterocyclic compounds as lasy activators Download PDF

Info

Publication number
WO2008036967A3
WO2008036967A3 PCT/US2007/079286 US2007079286W WO2008036967A3 WO 2008036967 A3 WO2008036967 A3 WO 2008036967A3 US 2007079286 W US2007079286 W US 2007079286W WO 2008036967 A3 WO2008036967 A3 WO 2008036967A3
Authority
WO
WIPO (PCT)
Prior art keywords
lasy
activators
heterocyclic compounds
novel heterocyclic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/079286
Other languages
French (fr)
Other versions
WO2008036967A2 (en
Inventor
Dumbala Srinivas Reddy
Indira Padmalayam
Debnath Bhuniya
Sivaram Pillarisetti
Ranjan Chakrabarti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reddy US Therapeutics Inc
Original Assignee
Reddy US Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy US Therapeutics Inc filed Critical Reddy US Therapeutics Inc
Publication of WO2008036967A2 publication Critical patent/WO2008036967A2/en
Publication of WO2008036967A3 publication Critical patent/WO2008036967A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a compound of formula (I), which is a free species and/or a pharmaceutically-acceptable salt or a stereoisomer of the compound of formula (I). Another aspect of the present invention provides the compound of the formula (I) as a Lipoic acid synthase (LASY) inducer
PCT/US2007/079286 2006-09-22 2007-09-24 Novel heterocyclic compounds as lasy activators Ceased WO2008036967A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84649906P 2006-09-22 2006-09-22
US60/846,499 2006-09-22

Publications (2)

Publication Number Publication Date
WO2008036967A2 WO2008036967A2 (en) 2008-03-27
WO2008036967A3 true WO2008036967A3 (en) 2008-09-18

Family

ID=39201359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079286 Ceased WO2008036967A2 (en) 2006-09-22 2007-09-24 Novel heterocyclic compounds as lasy activators

Country Status (1)

Country Link
WO (1) WO2008036967A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151211A1 (en) * 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
JP5921572B2 (en) 2011-01-04 2016-05-24 ノバルティス アーゲー Indole compounds or analogs useful for the treatment of age-related macular degeneration (AMD)
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
CN104379579B (en) 2012-06-28 2017-03-08 诺华股份有限公司 Pyrrolidin derivatives and its purposes as complement pathway regulator
EP2867224B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
AU2013288319A1 (en) 2012-07-12 2015-02-05 Novartis Ag Complement pathway modulators and uses thereof
GEP20217247B (en) * 2014-04-04 2021-04-26 Iomet Pharma Ltd Gb Indole derivatives for use in medicine
CN108602775B (en) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 Mast cell regulators and uses thereof
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
GB201704476D0 (en) 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
SG11202102791SA (en) 2018-09-25 2021-04-29 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
EP4100403A4 (en) 2020-02-04 2024-01-03 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196111B2 (en) * 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196111B2 (en) * 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

Also Published As

Publication number Publication date
WO2008036967A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008036967A3 (en) Novel heterocyclic compounds as lasy activators
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
WO2007085895A3 (en) Fap inhibitors
WO2007105058A3 (en) Pyrazole compounds
WO2008083248A3 (en) Cyclopamine analogs
SG171593A1 (en) Inhibitors of c-fms kinase
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2006133147A3 (en) Organic compounds
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2007003934A3 (en) 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2006052568A3 (en) Tgf-beta inhibitors
IL188661A0 (en) Amino acid salts of rosiglitazone
WO2006122216A3 (en) Processes for production of phenolic 4-biphenylylazetidin-2-ones
WO2007008684A3 (en) Ligands of melanocortin receptors
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
MY159913A (en) Dihydroetorphines and their preparation
WO2009040314A3 (en) Novel heteroaryl-substituted acetone derivatives, suitable for inhibiting phospholipase a2
WO2011064533A3 (en) Compositions containing a 3 - phenyluracil herbicide and a sulfamoylphenylurea safener
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2007081690A3 (en) Inhibitors of protein kinases
WO2007062314A3 (en) Heterocyclic cetp inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843055

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843055

Country of ref document: EP

Kind code of ref document: A2